


WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising an antisense oligonucleotide of formula I



(Formula I) and N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) or a salt thereof.

2. The pharmaceutical composition of claim 1, wherein the salt is a monosodium salt or a disodium salt.
3. The pharmaceutical composition of claim 1, further comprising a pH sensitive coating.
4. The pharmaceutical composition of claim 3, wherein the pH sensitive coating comprises a pH-sensitive hydrogel, a pH-activated drug delivery system, a pH-sensitive liposome, micelle or lipid nanoparticle, a pH-sensitive microsphere, a pH-sensitive nanoparticle, or any combination thereof.
5. The pharmaceutical composition of claim 1, further comprising one or more therapeutic agents selected from the group consisting of a statin, ezetimibe, a bile sequestering resin,

nicotinic acid, a fibric acid derivative, probucol, neomycin, dextrothyroxine, a plant stanol ester, a cholesterol absorption inhibitor, implitapide, an inhibitor of bile acid transporters, a regulator of hepatic CYP7a, an estrogen replacement therapeutic, and an anti-inflammatory.

6. The pharmaceutical composition of claim 5, wherein the statin is selected from the group consisting of lovastatin, cerivastatin, pravastatin, atorvastatin, simvastatin, rosuvastatin, and fluvastatin.
7. A tablet or capsule comprising
 - (i) (GalNAc)3-amino-hexamethylene- 5' phosphorothioyl)- 2'- O,4'-C-methylene Adenosyl-(3'>5' O,O-phosphorothioyl)- 2'- O,4'-C-methylene Adenosyl-(3'>5' O,O-phosphorothioyl)-2'- O,4'-C-methylene Thymidyl-(3'>5' O,O-phosphorothioyl)- 2'-deoxyGuanosyl-(3'>5' O,O-phosphorothioyl)- 2'-deoxyCytidyl-(3'>5' O,O-phosphorothioyl)-2'-deoxyThymidyl-(3'>5' O,O-phosphorothioyl)- 2'-deoxyAdenosyl-(3'>5' O,O-phosphorothioyl)- 2'-deoxyCytidyl-(3'>5' O,O-phosphorothioyl)- 2'-deoxyAdenosyl-(3'>5' O,O-phosphorothioyl)- 2'-deoxyAdenosyl-(3'>5' O,O-phosphorothioyl)- 2'-deoxyAdenosyl-(3'>5' O,O-phosphorothioyl)- 2'-deoxyCytidyl-(3'>5' O,O-phosphorothioyl)- 2'-O,4' C-methylene (5-methyl-Cytidyl)-(3'>5' O,O-phosphorothioyl)- 2'-O,4'-C-methylene (5-methyl-Cytidyl)-(3'>5' O,O-phosphorothioyl)- 2'-O,4'-C-methylene Adenosyl hexadeca sodium salt (CIVI 008), and
 - (ii) an 5-CNAC or a salt thereof, wherein the tablet or capsule comprises between 5 and 30 mg of CIVI 008 and between 100 and 200 mg of 5-CNAC.
8. The tablet or capsule of claim 7, wherein 5-CNAC is a monosodium salt, a disodium salt, or a combination thereof.
9. The tablet or capsule of claim 7, where CIVI 008 and 5-CNAC are in a dry blend.
10. The tablet or capsule of claim 7, wherein the capsule is a gelatin capsule.

11. The tablet or capsule of claim 7, wherein the tablet or capsule is enterically coated.
12. The tablet or capsule of claim 7, wherein the tablet or capsule comprises about 5 mg, about 10 mg, about 20 mg, about 25 mg, or about 30 mg of CIVI 008.
13. The tablet or capsule of claim 7, wherein the capsule comprises: (i) 10 mg of CIVI 008 and 100 mg of 5-CNAC; (ii) 20 mg of CIVI 008 and 200 mg of 5-CNAC; (iii) 5 mg of CIVI 008 and 200 mg of 5-CNAC; (iv) 10 mg of CIVI 008 and 200 mg of 5-CNAC; (v) 25 mg of CIVI 008 and 200 mg of 5-CNAC; or, (vi) 30 mg of CIVI 008 and 200 mg of 5-CNAC.
14. The tablet or capsule of claim 7, further containing a statin.
15. The tablet or capsule of claim 7, wherein the tablet or capsule has a weight between 5 mg and 1000 mg, 10 mg and 500 mg, 10 mg and 250 mg, 100 mg and 200 mg, or 250 mg and 500 mg.
16. The pharmaceutical composition of claim 1 or the tablet or capsule of claim 7 for use in therapy.
17. The pharmaceutical composition of claim 1 or the tablet or capsule of claim 7 for use in treating a disorder selected from the group consisting of atherosclerosis, hyperlipidemia, hypercholesterolemia, HDL/LDL cholesterol imbalance, coronary artery disease (CAD), or coronary heart disease (CHD).
18. The pharmaceutical composition of claim 1 or the tablet or capsule of claim 7 for use as a medicament to reduce expression levels and/or activity of PCSK9 in a subject or to reduce cholesterol levels in a subject.
19. The tablet or capsule for use according to any one of claims 16 to 18, wherein the tablet or capsule is suitable for administration at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 or 60 minutes prior to a meal.

20. A method to manufacture a capsule of claim 7 comprising:
- (i) dry blending a first composition comprising CIVI 008 and a second composition comprising 5-CNAC or a salt thereof; and,
 - (ii) encapsulating the resulting dry blend of step (i) in a capsule.